--- title: "Ulixacaltamide in Essential tremor: cost-effectiveness analyses and utility weights" description: "Published cost-effectiveness analyses and health-state utility weights for Ulixacaltamide in Essential tremor, each value quoted from the article: 6 cost-effectiveness analyses and 2 studies reporting utility weights. Analyses: Magnetic resonance-guided focused ultrasound versus no surgery, radiofrequency thalamotomy, and deep brain stimulation in medication-refractory essential tremor, Canada: Li et al. (2019); Unilateral magnetic resonance-guided focused ultrasound versus unilateral deep brain stimulation and versus no procedure in medically refractory essential tremor, England: Jameel et al. (2022); MR-guided focused ultrasound thalamotomy added to medical therapy, and deep brain stimulation, in tremor-dominant Parkinson's disease, Canada: Meng et al. (2021); Deep brain stimulation with medical therapy versus best medical therapy alone in advanced Parkinson's disease, United States: Pietzsch et al. (2016); 2 further articles. Utility weights: Utility weights for disabling essential tremor, tremor improvement after surgery, recurrence, and procedural complications: Li et al. (2019); Utility weights for disabling essential tremor and for tremor improvement after focused ultrasound or deep brain stimulation, with and without adverse events: Jameel et al. (2022). Every value is a verbatim quote from the primary article it is shown with." canonical: "https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses" published: "2026-10-22T07:49:06-04:00" modified: "2026-10-22T07:49:06-04:00" --- # Ulixacaltamide in Essential tremor: cost-effectiveness analyses and utility weights Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles. ## Overview | Item | Detail | | --- | --- | | Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. | | Cost-effectiveness analyses | 6 | | Studies reporting utility weights | 2 | ## 1 Cost-effectiveness analyses ### 1.1 Analyses of Ulixacaltamide No evidence found. ### 1.2 Treatments for the same indication #### Magnetic resonance-guided focused ultrasound versus no surgery, radiofrequency thalamotomy, and deep brain stimulation in medication-refractory essential tremor, Canada: Li et al. (2019) Relevance: Evaluates magnetic resonance-guided focused ultrasound thalamotomy against no surgery, radiofrequency thalamotomy, and deep brain stimulation in medication-refractory essential tremor from a Canadian public payer perspective, the analysis section 4.1 cites for the ablative and stimulation procedures listed in section 2. Access: Not open access Not quoted: The results for the comparisons with radiofrequency thalamotomy and deep brain stimulation are reported in the full text, which is closed access. > “We conducted a cost-utility analysis using a Markov cohort model.” > “We compared magnetic resonance-guided focused ultrasound with no surgery in people ineligible for invasive neurosurgery and with radiofrequency thalamotomy and deep brain stimulation in people eligible for invasive neurosurgery.” > “In the reference case analysis, we used a 5-year time horizon and a public payer perspective and discounted costs and benefits at 1.5% per year.” > “Compared with no surgery in people ineligible for invasive neurosurgery, magnetic resonance-guided focused ultrasound cost $21,438 more but yielded 0.47 additional quality-adjusted life years, producing an incremental cost-effectiveness ratio of $45,817 per quality-adjusted life year gained.” > “In people eligible for invasive neurosurgery, magnetic resonance-guided focused ultrasound was slightly less effective but much less expensive compared with the current standard of care, deep brain stimulation.” Source: [Li et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30589951/) #### Unilateral magnetic resonance-guided focused ultrasound versus unilateral deep brain stimulation and versus no procedure in medically refractory essential tremor, England: Jameel et al. (2022) Relevance: Evaluates unilateral magnetic resonance-guided focused ultrasound against unilateral deep brain stimulation and against no procedure in medically refractory essential tremor from the perspective of NHS England, procedures listed as treatment options in section 2. > “A Markov cohort model was developed to estimate the cost-effectiveness of MRgFUS in England as a treatment for moderate to severe mrET in England.” > “Cost-utility analysis performed from the perspective of NHS England.” > “3.5% discount rate was applied to costs and utilities in the model in line with NICE guidelines.” > “Model outcomes were the total costs per patient (2019 GBP) and quality-adjusted life-years (QALYs) for each strategy over a 5-year time horizon based on the available temporal data for MRgFUS.” > “MRgFUS was less costly (£19,779 vs £62,348) and more effective generating 0.03 additional QALYs (3.71 vs 3.68) per patient over the 5-year time horizon (Table 3).” > “Thus MRgFUS is economically dominant compared to DBS.” > “In patients not suitable for DBS, the MRgFUS strategy cost over £16,000 more than medication alone (£19,779 vs £3,735) but yielded 0.77 additional QALYs (3.71 vs 2.95) per patient, producing an ICER of £20,851 per QALY gained over a 5-year horizon.” > “When using a WTP threshold of £30,000, the MRgFUS strategy was more cost-effective than no procedure in 66% of the 1,000 iterations” Source: [Jameel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9733625/) ### 1.3 The same disease in other populations or settings No evidence found. ### 1.4 Related diseases and analogous treatments #### MR-guided focused ultrasound thalamotomy added to medical therapy, and deep brain stimulation, in tremor-dominant Parkinson's disease, Canada: Meng et al. (2021) Relevance: Evaluates magnetic resonance-guided focused ultrasound thalamotomy added to medical therapy, and deep brain stimulation, in tremor-dominant Parkinson's disease in Canada, a tremor disorder treated with the procedures section 2 lists for essential tremor. > “The authors used a decision tree model with rollback analysis and one-factor sensitivity analysis.” > “Costs in Canadian dollars (CAD) were derived from the Schedule of Benefits and Fees in Ontario, Canada, and expert opinion on usage.” > “MRgFUS was associated with an expected cost of $14,831 CAD.” > “Adding MRgFUS to continued medical therapy resulted in an incremental cost-effectiveness ratio of $30,078 per quality-adjusted life year (QALY), which remained cost-effective under various scenarios in the sensitivity analysis.” > “Comparing DBS to MRgFUS, while DBS did not achieve the willingness-to-pay threshold ($56,503 per QALY) in the base case scenario, it did so under several scenarios in the sensitivity analysis.” Source: [Meng et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32764177/) #### Deep brain stimulation with medical therapy versus best medical therapy alone in advanced Parkinson's disease, United States: Pietzsch et al. (2016) Relevance: Evaluates deep brain stimulation with medical therapy against best medical therapy alone in advanced Parkinson's disease from a United States Medicare payer perspective, the procedure section 2 lists for essential tremor. > “We used a decision-analytic state-transition (Markov) model to project PD progression and associated costs for the two treatment strategies.” > “We estimated the discounted incremental cost-effectiveness ratio (ICER) in U.S. dollars per quality-adjusted life-year (QALY) from the Medicare payer perspective, considering a ten-year horizon, and evaluated the robustness of our projections through extensive deterministic sensitivity analyses.” > “Over ten years, DBS treatment led to discounted total costs of $130,510 compared to $91,026 for BMT and added 1.69 QALYs more than BMT, resulting in an ICER of $23,404 per QALY.” > “This ICER was relatively insensitive to variations in input parameters, with neurostimulator replacement, costs for DBS implantation, and costs for treatment of disease-related falls having the greatest effects.” > “Across all investigated scenarios, including a five-year horizon, ICERs remained under $50,000 per QALY.” Source: [Pietzsch et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27491661/) #### Deep brain stimulation versus status before treatment in dystonia, United Kingdom: Yianni et al. (2005) Relevance: Evaluates deep brain stimulation against pretreatment status in dystonia in the United Kingdom, a related movement disorder treated with the procedure section 2 lists for refractory essential tremor. > “To perform a preliminary cost-utility and cost-benefit of deep brain stimulation (DBS) in the treatment of dystonia” > “We conducted a prospective study of 26 patients undergoing DBS for the treatment of dystonia.” > “We performed a cost-utility analysis using the Euroquol (EQ-5D) questionnaire.” > “We found that the EQ-5D score improved from 29 to 76.2 points after surgery, an incremental utility of 0.47.” > “There was an overall gain of 0.94 quality-adjusted life-years (QALY) with a cost of £33,980 per QALY.” Source: [Yianni et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/22151484/) #### AbobotulinumtoxinA versus best supportive care in cervical dystonia, United Kingdom: Muthukumar et al. (2017) Relevance: Evaluates abobotulinumtoxinA against best supportive care in cervical dystonia over a lifetime horizon in the United Kingdom, the botulinum toxin treatment section 2 lists for refractory essential tremor applied in a related movement disorder. > “A Markov model was developed to evaluate the cost-effectiveness of abobotulinum-toxinA versus best supportive care (BSC) in CD, with a lifetime horizon and health states for response, nonresponse, secondary nonresponse, and BSC in patients with CD (mean age: 53 years; 37% male).” > “The analysis adopted the perspective of the UK NHS and PSS.” > “Model costs and outcomes were discounted at 3.5% per annum based on the National Institute for Health and Care Excellence reference case.” > “The currency year for the analyses was 2013.” > “The total incremental QALYs gained from abobotulinumtoxinA compared to BSC was 0.235 per patient, with the total incremental cost being £7,160. This corresponds to an ICER of £30,468 per QALY gained.” > “Changing the time horizon to 5 years resulted in total incremental costs of £2,809, incremental QALYs of 0.083, and an ICER of £38,117.” > “The CEAC showed that abobotulinumtoxinA had a 46% probability of being cost-effective at a threshold of £20,000 compared to BSC without BoNT-A injections.” Source: [Muthukumar et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5402907/) ## 2 Utility weights ### 2.1 Utility weights from analyses of Ulixacaltamide No evidence found. ### 2.2 Utility weights for the same indication No evidence found. ### 2.3 Utility weights for the same disease in other populations or settings #### Utility weights for disabling essential tremor, tremor improvement after surgery, recurrence, and procedural complications: Li et al. (2019) Relevance: Utilities for disabling essential tremor, tremor improvement after surgery, tremor recurrence, and procedural complications, from a Canadian model of magnetic resonance-guided focused ultrasound. Access: Not open access Not quoted: The utility weights are reported in the full text, which is closed access. Source: [Li et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30589951/) #### Utility weights for disabling essential tremor and for tremor improvement after focused ultrasound or deep brain stimulation, with and without adverse events: Jameel et al. (2022) Relevance: Utilities for disabling essential tremor at baseline and for marked or mild to moderate improvement after focused ultrasound or deep brain stimulation, with and without adverse events, in the short and long term. > “Values included the utility in each health state, and the disutility incurred from treatment-related adverse events.” Source: [Jameel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9733625/) | Health state | Utility | | --- | --- | | “Alive with disabling tremor (baseline)” | “0.69” | | “Improved tremor post-procedure (marked improvement – no adverse events)” | “0.91” | | “Improved tremor post-procedure (mild to moderate improvement – no adverse events)” | “0.80” | | “Improved tremor post-procedure with adverse events (marked improvement) (MRgFUS)” “Short term (year 1)” | “0.91” | | “Improved tremor post-procedure with adverse events (marked improvement) (MRgFUS)” “Long term (year 2+)” | “0.90” | | “Improved tremor post-procedure with adverse events (marked improvement) (DBS)” “Short term (year 1)” | “0.91” | | “Improved tremor post-procedure with adverse events (marked improvement) (DBS)” “Long term (year 2+)” | “0.91” | | “Improved tremor post-procedure with adverse events (mild/moderate improvement) (MRgFUS)” “Short term (year 1)” | “0.80” | | “Improved tremor post-procedure with adverse events (mild/moderate improvement) (MRgFUS)” “Long term (year 2+)” | “0.79” | | “Improved tremor post-procedure with adverse events (mild/moderate improvement) (DBS)” “Short term (year 1)” | “0.80” | | “Improved tremor post-procedure with adverse events (mild/moderate improvement) (DBS)” “Long term (year 2+)” | “0.76” | Source: [Jameel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9733625/) ### 2.4 Utility weights for related diseases and analogous treatments No evidence found. ## 3 Search strategy | Dataset | Query | Results | | --- | --- | --- | | Methods | ulixacaltamide OR "PRAX-944" OR "Z944" | 0 | | Ratios | "essential tremor" OR "tremor" | 7 | | Methods | "essential tremor" OR tremor | 4 | | Ratios | "focused ultrasound" OR thalamotomy OR "radiosurgery" AND tremor | 0 | | Methods | "focused ultrasound" | 14 | | Ratios | propranolol OR primidone OR topiramate | 140 | | Weights | "essential tremor" OR tremor | 45 | | Ratios | "deep brain stimulation" | 64 | | Ratios | ethosuximide OR "T-type calcium" | 0 | | Ratios | "cervical dystonia" OR dystonia | 11 | | Ratios | "peripheral nerve stimulation" OR "transcutaneous afferent patterned stimulation" | 0 | | Methods | primidone | 0 | | Ratios | thalamotomy OR "radiofrequency thalamotomy" OR "gamma knife" | 12 | ## Related pages - [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor.md) - [Ulixacaltamide in Essential tremor: Terms and abbreviations](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations.md) - [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary.md) - [Ulixacaltamide in Essential tremor: Product information and disease description](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description.md) - [Ulixacaltamide in Essential tremor: Clinical evidence](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence.md) - [Ulixacaltamide in Essential tremor: Economic information and modeling report](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics.md) - [Ulixacaltamide in Essential tremor: References](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references.md) - [Ulixacaltamide in Essential tremor: prevalence by geography](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence.md)